| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Javier Molina-Cerrillo | Q90613337 |
| P2093 | author name string | Alfredo Carrato | |
| Pilar Garrido | |||
| Enrique Grande | |||
| Teresa Alonso-Gordoa | |||
| María Laura García-Bermejo | |||
| P2860 | cites work | Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† | Q91784083 |
| Involvement of platelet-derived growth factor ligands and receptors in tumorigenesis | Q47756210 | ||
| Discovery of dual Axl/VEGF-R2 inhibitors as potential anti-angiogenic and anti-metastatic drugs for cancer chemotherapy. | Q47826183 | ||
| The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders | Q50142390 | ||
| The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis | Q22009936 | ||
| Mechanism of action and in vivo role of platelet-derived growth factor | Q22010594 | ||
| Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity | Q22254157 | ||
| A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells | Q24291278 | ||
| Identification of the Hepatocyte Growth Factor Receptor As the c- met Proto-Oncogene Product | Q24310794 | ||
| The protein kinase complement of the human genome | Q24324497 | ||
| Binding of the von Hippel-Lindau Tumor Suppressor Protein to Elongin B and C | Q24336712 | ||
| Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo | Q24648140 | ||
| Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications | Q26801718 | ||
| Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer | Q27824855 | ||
| Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation | Q27852038 | ||
| Comprehensive molecular characterization of clear cell renal cell carcinoma | Q27852374 | ||
| Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy | Q28070028 | ||
| Fibroblast growth factors, their receptors and signaling | Q28140520 | ||
| c-Met: structure, functions and potential for therapeutic inhibition | Q28190143 | ||
| Met, metastasis, motility and more | Q28235183 | ||
| Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma | Q28247085 | ||
| Sunitinib versus interferon alfa in metastatic renal-cell carcinoma | Q28282757 | ||
| Sorafenib in advanced clear-cell renal-cell carcinoma | Q28282767 | ||
| Axitinib Versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial | Q51589013 | ||
| Ankyrin repeat and Single KH domain 1 (ANKHD1) drives renal cancer cell proliferation via binding to and altering a subset of miRNAs. | Q52562962 | ||
| Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma | Q52644831 | ||
| Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. | Q52650529 | ||
| Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study. | Q52652060 | ||
| Axl inhibitors as novel cancer therapeutic agents. | Q52678542 | ||
| Renal cell carcinoma: a review of biology and pathophysiology. | Q52724797 | ||
| RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial | Q53197402 | ||
| Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study. | Q53368038 | ||
| The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer | Q54298179 | ||
| Targeting MET in cancer therapy. | Q54987450 | ||
| Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. | Q55067769 | ||
| Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma | Q56373211 | ||
| Future applications of FGF/FGFR inhibitors in cancer | Q57163702 | ||
| The role of PDGF-B/PDGFR-BETA axis in the normal development and carcinogenesis of the breast | Q57181165 | ||
| Extracellular Matrix Influencing HGF/c-MET Signaling Pathway: Impact on Cancer Progression | Q57791826 | ||
| Role of HIF-1 in cancer progression: novel insights. A review | Q58563167 | ||
| Status of Agents Targeting the HGF/c-Met Axis in Lung Cancer | Q58726253 | ||
| PDGF/PDGFR effects in osteosarcoma and the "add-on" strategy | Q58803894 | ||
| Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial | Q59571527 | ||
| Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries | Q60142201 | ||
| Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma | Q60164660 | ||
| Activated Rho GTPases in Cancer-The Beginning of a New Paradigm | Q60907791 | ||
| HGF/c-MET Signaling in Melanocytes and Melanoma | Q60920855 | ||
| Post-Translational Modification and Subcellular Distribution of Rac1: An Update | Q60959651 | ||
| Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma | Q62514960 | ||
| Phytochemicals Targeting VEGF and VEGF-Related Multifactors as Anticancer Therapy | Q64103615 | ||
| Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma | Q73798005 | ||
| The clinical significance of platelet-derived growth factors (PDGFs) and their receptors (PDGFRs) in gastric cancer: A systematic review and meta-analysis | Q89067156 | ||
| Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial | Q90447266 | ||
| Combination Therapy as First-Line Treatment in Metastatic Renal-Cell Carcinoma | Q91700780 | ||
| Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma | Q91700806 | ||
| Regulation of c-Met-dependent gene expression by PTEN | Q28290742 | ||
| Tubby and tubby-like protein 1 are new MerTK ligands for phagocytosis | Q28513697 | ||
| Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012 | Q29615661 | ||
| Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors | Q29616545 | ||
| Fibroblast growth factor signalling: from development to cancer | Q29616827 | ||
| Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial | Q29618031 | ||
| Identification of the von Hippel-Lindau disease tumor suppressor gene | Q29618644 | ||
| Renal cell carcinoma | Q30235364 | ||
| Renal cell cancer stage migration: analysis of the National Cancer Data Base | Q31156006 | ||
| Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer | Q33369361 | ||
| Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial | Q33385435 | ||
| Pazopanib versus sunitinib in metastatic renal-cell carcinoma | Q33409916 | ||
| Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies | Q33439519 | ||
| Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study | Q33510317 | ||
| Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. | Q33880227 | ||
| Galectin-3 is a new MerTK-specific eat-me signal | Q33972695 | ||
| Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial | Q33997879 | ||
| The genetic basis of kidney cancer: a metabolic disease | Q34087148 | ||
| Endothelial Akt1 mediates angiogenesis by phosphorylating multiple angiogenic substrates | Q34144300 | ||
| Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET. | Q34217927 | ||
| A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. | Q34322740 | ||
| Emerging principles for the therapeutic exploitation of glycosylation. | Q34395447 | ||
| The Fibroblast Growth Factor signaling pathway | Q34467171 | ||
| Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma | Q34495684 | ||
| Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. | Q34633525 | ||
| Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial | Q34650664 | ||
| TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer | Q34794927 | ||
| Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial | Q35195766 | ||
| Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs | Q35881802 | ||
| phospholipase C gamma-1 is required downstream of vascular endothelial growth factor during arterial development | Q35965422 | ||
| P2Y₂ and Gq/G₁₁ control blood pressure by mediating endothelial mechanotransduction. | Q36040517 | ||
| Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. | Q36281483 | ||
| Distinct activation properties of the nuclear factor of activated T-cells (NFAT) isoforms NFATc3 and NFATc4 in neurons. | Q36368164 | ||
| c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy | Q36731520 | ||
| VEGFR2 pY949 signalling regulates adherens junction integrity and metastatic spread | Q36747249 | ||
| VEGFR-2 conformational switch in response to ligand binding. | Q36791927 | ||
| Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors | Q37069569 | ||
| The strong dimerization of the transmembrane domain of the fibroblast growth factor receptor (FGFR) is modulated by C-terminal juxtamembrane residues | Q37255433 | ||
| Regulation of nuclear factor of activated T cells (NFAT) in vascular endothelial cells. | Q37426782 | ||
| New strategies in kidney cancer: therapeutic advances through understanding the molecular basis of response and resistance | Q37697369 | ||
| PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes | Q37727180 | ||
| NFAT, immunity and cancer: a transcription factor comes of age | Q37781277 | ||
| Developmental and pathological angiogenesis | Q37901035 | ||
| Role of FGFs/FGFRs in skeletal development and bone regeneration | Q37989404 | ||
| Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial | Q38135798 | ||
| Isoforms of receptors of fibroblast growth factors | Q38204716 | ||
| International variations and trends in renal cell carcinoma incidence and mortality. | Q38275510 | ||
| A phase I study of cabozantinib (XL184) in patients with renal cell cancer. | Q38430335 | ||
| Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma | Q38655126 | ||
| FGFR a promising druggable target in cancer: Molecular biology and new drugs. | Q38692628 | ||
| Bruton's tyrosine kinase (BTK) as a promising target in solid tumors | Q38713716 | ||
| HIF-1 in cancer therapy: two decade long story of a transcription factor. | Q38737693 | ||
| Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells | Q38798978 | ||
| Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma | Q38835745 | ||
| Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. | Q38859789 | ||
| Mechanisms and regulation of endothelial VEGF receptor signalling. | Q38909541 | ||
| Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases | Q38912985 | ||
| The basis for the distinct biological activities of vascular endothelial growth factor receptor-1 ligands. | Q39131192 | ||
| Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies | Q39157476 | ||
| miRNAs: micro-managers of anticancer combination therapies. | Q39285150 | ||
| TAM Receptor Tyrosine Kinases in Cancer Drug Resistance | Q39319172 | ||
| AXL-Driven EMT State as a Targetable Conduit in Cancer | Q39408053 | ||
| Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study. | Q40022143 | ||
| The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing | Q40536461 | ||
| Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma | Q41316099 | ||
| Molecular controls of lymphatic VEGFR3 signaling | Q42094869 | ||
| Mutations of the VHL tumour suppressor gene in renal carcinoma | Q42806703 | ||
| Novel mutations of the MET proto-oncogene in papillary renal carcinomas. | Q42815807 | ||
| A clear picture of renal cell carcinoma | Q45674698 | ||
| A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period | Q46769349 | ||
| The target landscape of clinical kinase drugs | Q47345032 | ||
| PLCγ1: Potential arbitrator of cancer progression | Q47366236 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | neovascularization | Q1281049 |
| angiogenesis inhibitor | Q574834 | ||
| signal transduction | Q828130 | ||
| renal cell carcinoma | Q1164529 | ||
| kidney neoplasm | Q13641482 | ||
| Fibroblast Growth Factor Receptor (FGFR) | Q63966056 | ||
| P304 | page(s) | 1901 | |
| P577 | publication date | 2019-04-17 | |
| P1433 | published in | International Journal of Molecular Sciences | Q3153277 |
| P1476 | title | Targeting Tyrosine kinases in Renal Cell Carcinoma: "New Bullets against Old Guys" | |
| P478 | volume | 20 |
| Q90245952 | Di-Ras2 promotes renal cell carcinoma formation by activating the mitogen-activated protein kinase pathway in the absence of von Hippel-Lindau protein |
| Q132660606 | Honokiol: A review of its pharmacological potential and therapeutic insights |
| Q96123488 | MMPs, tyrosine kinase signaling and extracellular matrix proteolysis in kidney cancer |
Search more.